NORWOOD,
Mass., April 8, 2022 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), an immunology company, announced today the first
preclinical data for CRB-601 are being presented in a poster at the
American Association for Cancer Research (AACR) Annual Meeting
being held from April 8-13, 2022, in
New Orleans, LA. CRB-601 is a
potent and selective αvb8 integrin monoclonal antibody designed to
block the activation of TGFb in the local tumor
microenvironment. TGFb is thought to be the only ligand of the
αvb8 integrin. Inhibiting its ability to bind to αvb8 could
therefore play an important role in the regulation of this
pleiotropic cytokine. The in vitro preclinical data
presented demonstrate the high affinity of CRB-601 for αvb8 and the
resulting effect on TGFb. The data also show significant inhibition
of tumor growth in a syngeneic model of colon cancer (MC38) by
CRB-601, both as a single agent and in combination with anti PD-1
treatment. These effects are supported by the coincident increase
in CD8-positive T cells in the tumor microenvironment.
"The increase of tumor infiltration by T-cells stimulated by
CRB-601 is quite exciting. The effects of CRB-601 are consistent
with the proposed mechanism of blocking TGFb activation, which
can potentially enable an anti-tumor immune response and be an
effective adjunct to immune checkpoint therapies. We are excited to
bring this mechanism of action to the clinic and define the
potential benefit it could bring to patients," commented
Rachael Brake, Ph.D., Chief
Scientific Officer of Corbus.
Corbus is currently developing CRB-601 as a potential treatment
for solid tumor cancers, and the program is advancing toward an IND
submission in the first half of 2023.
The AACR poster is available on the Company's website at:
www.corbuspharma.com/AACRposter
Additionally, Corbus has published an updated Corporate
Presentation providing an overview of the Company's full portfolio
on its website at: ir.corbuspharma.com/presentations
About Corbus
Corbus is an immunology company committed to connecting
innovation to our purpose of improving lives by developing new
medicines that target the nexus between the immune system and
cancer. Corbus' current pipeline includes anti-integrin monoclonal
antibodies that block activation of TGFβ and small molecules that
activate or inhibit the endocannabinoid system. Corbus is
headquartered in Norwood,
Massachusetts. For more information on Corbus, visit
corbuspharma.com. Connect with us on Twitter, LinkedIn and
Facebook.
Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's restructuring, trial results, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the
negatives of those terms. These statements relate to future events
or our financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
INVESTOR CONTACT:
Brian
Walsh
VP, Corporate Development
brian.walsh@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-presents-first-preclinical-data-for-crb-601-at-the-american-association-for-cancer-research-aacr-annual-meeting-301520598.html
SOURCE Corbus Pharmaceuticals